JP2008542440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008542440A5 JP2008542440A5 JP2008515384A JP2008515384A JP2008542440A5 JP 2008542440 A5 JP2008542440 A5 JP 2008542440A5 JP 2008515384 A JP2008515384 A JP 2008515384A JP 2008515384 A JP2008515384 A JP 2008515384A JP 2008542440 A5 JP2008542440 A5 JP 2008542440A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- use according
- pain
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 33
- 208000002193 Pain Diseases 0.000 claims 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 208000000094 Chronic Pain Diseases 0.000 claims 5
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000009519 contusion Effects 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000025661 ovarian cyst Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000290A ITRM20050290A1 (it) | 2005-06-07 | 2005-06-07 | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM2005A000290 | 2005-06-07 | ||
| PCT/IT2006/000427 WO2006131952A1 (en) | 2005-06-07 | 2006-06-07 | Novel analgesic treatment with prolonged effect |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013037304A Division JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008542440A JP2008542440A (ja) | 2008-11-27 |
| JP2008542440A5 true JP2008542440A5 (OSRAM) | 2009-07-23 |
| JP5730464B2 JP5730464B2 (ja) | 2015-06-10 |
Family
ID=37056613
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515384A Expired - Fee Related JP5730464B2 (ja) | 2005-06-07 | 2006-06-07 | 延長効果をもつ新規鎮痛治療 |
| JP2008515383A Expired - Fee Related JP5133879B2 (ja) | 2005-06-07 | 2006-06-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2012106277A Withdrawn JP2012158604A (ja) | 2005-06-07 | 2012-05-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2013037304A Pending JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
| JP2014163809A Pending JP2014218513A (ja) | 2005-06-07 | 2014-08-11 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515383A Expired - Fee Related JP5133879B2 (ja) | 2005-06-07 | 2006-06-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2012106277A Withdrawn JP2012158604A (ja) | 2005-06-07 | 2012-05-07 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
| JP2013037304A Pending JP2013151509A (ja) | 2005-06-07 | 2013-02-27 | 延長効果をもつ新規鎮痛治療 |
| JP2014163809A Pending JP2014218513A (ja) | 2005-06-07 | 2014-08-11 | ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8691221B2 (OSRAM) |
| EP (3) | EP1890726B1 (OSRAM) |
| JP (5) | JP5730464B2 (OSRAM) |
| KR (1) | KR101486085B1 (OSRAM) |
| CN (1) | CN101277718B (OSRAM) |
| AU (1) | AU2006256387B2 (OSRAM) |
| CA (2) | CA2610596A1 (OSRAM) |
| DK (1) | DK1890726T3 (OSRAM) |
| IT (1) | ITRM20050290A1 (OSRAM) |
| MX (1) | MX2007015487A (OSRAM) |
| NO (1) | NO20080084L (OSRAM) |
| NZ (1) | NZ564071A (OSRAM) |
| RU (1) | RU2427387C2 (OSRAM) |
| WO (2) | WO2006131951A2 (OSRAM) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| MX2009006594A (es) * | 2006-12-21 | 2009-08-12 | Amgen Inc | Formulaciones de ph regulado y estables que contienen polipeptidos. |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY161564A (en) | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| WO2009077993A2 (en) | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
| AU2009211340B2 (en) * | 2008-02-04 | 2013-09-12 | Lay Line Genomics S.P.A. | Anti-TrkA antibodies and derivatives thereof |
| JP5646457B2 (ja) | 2008-04-29 | 2014-12-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20100054A1 (es) | 2008-06-03 | 2010-03-03 | Abbott Lab | Inmunoglobulina con dominio variable dual |
| WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
| MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| CA2736864C (en) | 2008-09-19 | 2020-10-13 | Pfizer Inc. | Stable liquid antibody formulation |
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| CN106336400A (zh) * | 2008-12-08 | 2017-01-18 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| BRPI1008692B8 (pt) * | 2009-02-17 | 2021-05-25 | Ucb Biopharma Sprl | anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão |
| KR20120088550A (ko) * | 2009-05-04 | 2012-08-08 | 애보트 리서치 비.브이. | 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체 |
| WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| AR078254A1 (es) * | 2009-09-01 | 2011-10-26 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| MX2012004415A (es) * | 2009-10-15 | 2012-05-08 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| PH12013500337A1 (en) | 2010-08-26 | 2017-08-23 | Abbvie Inc | Dual variable domain immunoglobulins and uses thereof |
| NZ611076A (en) | 2010-12-01 | 2015-09-25 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| AU2012252152B2 (en) * | 2011-05-06 | 2016-07-07 | Zoetis Services Llc | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| PL3498732T3 (pl) | 2011-05-06 | 2022-02-28 | Zoetis Services Llc | Przeciwciała przeciw czynnikowi wzrostu nerwów oraz sposoby ich otrzymywania i zastosowania |
| US20140170136A1 (en) | 2011-05-06 | 2014-06-19 | Nvip Pty Ltd. | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| CA2835094C (en) * | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| US9580496B2 (en) | 2011-05-06 | 2017-02-28 | Nexvet Australia Pty Ltd | Therapeutic canine immunoglobulins and methods of using same |
| SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
| NZ732875A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| RS66303B1 (sr) | 2011-05-20 | 2025-01-31 | H Lundbeck As | Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene |
| US9102673B2 (en) | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| US8926978B2 (en) | 2011-10-25 | 2015-01-06 | Anaptysbio, Inc. | Antibodies directed against nerve growth factor (NGF) |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
| JP2015503592A (ja) * | 2012-01-05 | 2015-02-02 | ビーチ ツリー ラボ、インコーポレイテッド | 神経成長因子の投与による疼痛処置方法 |
| US9181261B2 (en) | 2012-05-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | TrkA kinase inhibitors, compositions and methods thereof |
| JP6629069B2 (ja) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | イヌ化抗ｎｇｆ抗体およびその方法 |
| SG11201408037SA (en) * | 2012-06-08 | 2015-01-29 | Glenmark Pharmaceuticals Sa | Humanized anti-trka antibodies with amino acid substitutions |
| EP2674439B1 (en) | 2012-06-13 | 2017-02-01 | Rottapharm Biotech S.r.l. | Anti-TrkA antibodies, derivatives and uses thereof |
| AU2013337775B2 (en) | 2012-11-01 | 2017-03-30 | Abbvie Inc. | Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof |
| EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| WO2015039334A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2015039333A1 (en) | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2015120136A1 (en) | 2014-02-05 | 2015-08-13 | VM Oncology LLC | Compositions of compounds and uses thereof |
| WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| MA41097A (fr) * | 2014-12-05 | 2017-10-10 | Glenmark Pharmaceuticals Sa | Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| BR112017015760A2 (pt) | 2015-01-23 | 2018-03-27 | Gvk Biosciences Private Limited | inibidores de quinase trka |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| KR20180021745A (ko) | 2015-06-01 | 2018-03-05 | 록쏘 온콜로지, 인코포레이티드 | 암을 진단하고 치료하는 방법 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| HUE053067T2 (hu) | 2015-07-16 | 2021-06-28 | Array Biopharma Inc | Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| ES2987501T3 (es) | 2016-04-04 | 2024-11-15 | Loxo Oncology Inc | Métodos de tratamiento de cánceres pediátricos |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| WO2019084285A1 (en) | 2017-10-26 | 2019-05-02 | Qian Zhao | FORMULATIONS OF A MACROCYCLIC TRK KINASE INHIBITOR |
| CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| AR114110A1 (es) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | Anticuerpo anti-trka |
| MX2020009526A (es) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anticuerpos anti-ngf y metodos de estos. |
| CA3095366A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| JP2022500383A (ja) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物 |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| PE20211707A1 (es) | 2019-01-08 | 2021-09-01 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp |
| JP7671699B2 (ja) * | 2019-05-30 | 2025-05-02 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 抗ＴｒｋＡ抗体及びその使用 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| AU2020204105B2 (en) * | 2020-06-19 | 2023-06-08 | Dartsbio Pharmaceuticals Ltd. | Anti-human ngf antibodies and methods using same |
| US11655292B2 (en) | 2020-06-23 | 2023-05-23 | Ampsource Biopharma Shanghai Inc. | Anti-human NGF antibodies and methods using same |
| EP4308101A1 (en) * | 2021-04-21 | 2024-01-24 | Redyneuheart S.r.l. | N-acetyl cysteine for neuraxial use as a trka tyrosine kinase receptor inhibitor for the treatment of acute and chronic pain |
| IL311096A (en) * | 2021-08-31 | 2024-04-01 | Scout Bio Inc | Antigen binding molecules and their uses |
| JP2025503539A (ja) | 2021-12-28 | 2025-02-04 | ４ビー テクノロジーズ（スーヂョウ） リミテッド | ＴｒｋＡ抗体とその応用 |
| EP4316481A1 (en) | 2022-08-01 | 2024-02-07 | Edmond Pharma S.R.L. | Erdosteine, salts, enantiomers or metabolites thereof for use in the treatment of acute and chronic pain states |
| US20250122291A1 (en) | 2023-10-13 | 2025-04-17 | Cephalon Llc | Anti-trka antibodies and uses thereof |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230691A (en) * | 1978-05-23 | 1980-10-28 | The Massachusetts General Hospital | Nerve growth factor antibody and process |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE465573B (sv) | 1989-03-14 | 1991-09-30 | Lope Medicine Ab | Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor |
| US5147294A (en) * | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
| WO1992008483A1 (en) | 1990-11-13 | 1992-05-29 | The Children's Medical Center Corporation | CONTROLLING β-AMYLOID RELATED NEURONAL DEGENERATION BY ANTAGONIZING NGF-EFFECTED NEURONAL ACTIVITY |
| JPH06503722A (ja) | 1990-11-30 | 1994-04-28 | アボット・ラボラトリーズ | 末端欠失神経成長因子受容体の検出に有用なイムノアッセイおよびモノクローナル抗体 |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| SG49597A1 (en) | 1992-02-06 | 1998-06-15 | Schering Corp | Design cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
| EP0578515A3 (en) | 1992-05-26 | 1995-05-10 | Bristol Myers Squibb Co | Humanized monoclonal antibodies. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9402331D0 (en) * | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5747060A (en) * | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
| DE19732928C2 (de) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| DE60044149D1 (de) | 1999-08-06 | 2010-05-20 | S I S S A Scuola Internaz Supe | Transgene mäuse zur studierung von neurodegenerativen syndromen |
| WO2001052843A1 (en) * | 2000-01-18 | 2001-07-26 | Mcgill University | β-TURN PEPTIDOMIMETIC CYCLIC COMPOUNDS |
| US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| HK1049184A1 (zh) | 2000-03-16 | 2003-05-02 | Genentech, Inc. | 具有增强抗凝血效能的抗组织因子抗体 |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| AU2001288374A1 (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| US7507799B2 (en) * | 2001-05-25 | 2009-03-24 | Cornell Research Foundation, Inc. | High affinity ligand for p75 neurotrophin receptor |
| EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
| SE0102067D0 (sv) | 2001-06-11 | 2001-06-11 | A & Science Invest Ab | Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation |
| AU2002324556A1 (en) * | 2001-07-25 | 2003-02-17 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP3729841B2 (ja) * | 2001-10-15 | 2005-12-21 | 麒麟麦酒株式会社 | 抗ｈｌａ−ｄｒ抗体の利用 |
| US6919426B2 (en) * | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
| CA2500901A1 (en) * | 2002-10-04 | 2004-04-22 | Rinat Neuroscience Corp. | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| EP1556083B1 (en) * | 2002-10-08 | 2011-02-02 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by admisnistering an antibody against nerve growth factor and compositions containing the same |
| US7255860B2 (en) * | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
| ATE545429T1 (de) * | 2002-12-20 | 2012-03-15 | Lundbeck & Co As H | Modulation der neurotrophinaktivität;screeningsverfahren |
| EP2270048B1 (en) | 2002-12-24 | 2015-11-11 | Rinat Neuroscience Corp. | Anti-NGF antibodies and methods using same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US20040131515A1 (en) * | 2003-01-03 | 2004-07-08 | Alexanian Ara J. | Material heat treatment system and method statement regarding federally sponsored research or development |
| WO2004065560A2 (en) | 2003-01-18 | 2004-08-05 | Rinat Neuroscience Corp. | Methods of screening for modulators of nerve growth factor |
| KR20050111598A (ko) * | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| MEP31508A (hr) * | 2003-07-15 | 2010-10-10 | Amgen Inc | Humana anti-ngf neutrališuća antitijela kao selektivni ihibitori ngf signalne kaskade |
| WO2005044293A2 (en) | 2003-11-07 | 2005-05-19 | Lay Line Genomics S.P.A. | Compositions able to prevent neurodegenerative processes and methods of assaying the same |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7522822B2 (en) * | 2004-01-06 | 2009-04-21 | Robert Trujillo | Halogen lamp assembly with integrated heat sink |
| AU2005243247B2 (en) * | 2004-04-07 | 2012-03-01 | Regents Of The University Of Minnesota | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| ITRM20040212A1 (it) | 2004-04-30 | 2004-07-30 | Lay Line Genomics Spa | Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce. |
| ME00226B (me) * | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
| EP2298345A3 (en) * | 2005-01-24 | 2012-03-21 | MedImmune Limited | Specific binding members for NGF |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| MX2009006594A (es) * | 2006-12-21 | 2009-08-12 | Amgen Inc | Formulaciones de ph regulado y estables que contienen polipeptidos. |
| JP6071165B2 (ja) * | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| US8309088B2 (en) * | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| MY161564A (en) * | 2007-08-10 | 2017-04-28 | Regeneron Pharma | High affinity human antibodies to human nerve growth factor |
| WO2009077993A2 (en) | 2007-12-17 | 2009-06-25 | Pfizer Limited | Treatment of interstitial cystitis |
| AU2009211340B2 (en) | 2008-02-04 | 2013-09-12 | Lay Line Genomics S.P.A. | Anti-TrkA antibodies and derivatives thereof |
| CA2782712A1 (en) | 2010-02-03 | 2011-08-11 | Morinaga Milk Industry Co., Ltd. | Method for manufacturing aloe powder |
| EP2547365A1 (en) | 2010-03-17 | 2013-01-23 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
-
2005
- 2005-06-07 IT IT000290A patent/ITRM20050290A1/it unknown
-
2006
- 2006-06-07 NZ NZ564071A patent/NZ564071A/en not_active IP Right Cessation
- 2006-06-07 WO PCT/IT2006/000426 patent/WO2006131951A2/en not_active Ceased
- 2006-06-07 RU RU2007147625/15A patent/RU2427387C2/ru not_active IP Right Cessation
- 2006-06-07 AU AU2006256387A patent/AU2006256387B2/en not_active Ceased
- 2006-06-07 EP EP06756318.9A patent/EP1890726B1/en active Active
- 2006-06-07 CN CN2006800288760A patent/CN101277718B/zh not_active Expired - Fee Related
- 2006-06-07 US US11/921,398 patent/US8691221B2/en not_active Expired - Fee Related
- 2006-06-07 MX MX2007015487A patent/MX2007015487A/es active IP Right Grant
- 2006-06-07 KR KR1020087000315A patent/KR101486085B1/ko not_active Expired - Fee Related
- 2006-06-07 DK DK06756318.9T patent/DK1890726T3/en active
- 2006-06-07 EP EP11188102A patent/EP2484380A1/en not_active Withdrawn
- 2006-06-07 CA CA002610596A patent/CA2610596A1/en not_active Abandoned
- 2006-06-07 WO PCT/IT2006/000427 patent/WO2006131952A1/en not_active Ceased
- 2006-06-07 JP JP2008515384A patent/JP5730464B2/ja not_active Expired - Fee Related
- 2006-06-07 EP EP06756317A patent/EP1893234A2/en not_active Withdrawn
- 2006-06-07 JP JP2008515383A patent/JP5133879B2/ja not_active Expired - Fee Related
- 2006-06-07 CA CA2611433A patent/CA2611433C/en active Active
- 2006-06-07 US US11/921,826 patent/US9688749B2/en not_active Expired - Fee Related
-
2008
- 2008-01-07 NO NO20080084A patent/NO20080084L/no unknown
-
2012
- 2012-05-07 JP JP2012106277A patent/JP2012158604A/ja not_active Withdrawn
-
2013
- 2013-02-27 JP JP2013037304A patent/JP2013151509A/ja active Pending
-
2014
- 2014-08-11 JP JP2014163809A patent/JP2014218513A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008542439A5 (OSRAM) | ||
| RU2007147625A (ru) | МОЛЕКУЛЫ, СПОСОБНЫЕ ИНГИБИРОВАТЬ СВЯЗЫВАНИЕ МЕЖДУ NGF И РЕЦЕПТОРОМ TrkA, В КАЧЕСТВЕ АНАЛЬГЕТИКОВ С ПРОЛОНГИРОВАННЫМ ЭФФЕКТОМ | |
| JP2020062036A5 (OSRAM) | ||
| HRP20191999T1 (hr) | Monoklonska protutijela anti-faktora xi i postupci njihove uporabe | |
| JP2012511913A5 (OSRAM) | ||
| RU2017102193A (ru) | Конструкции полиспецифических антител | |
| JP2022553324A5 (OSRAM) | ||
| RU2012128651A (ru) | Антитела, связывающиеся преимущественно с внеклеточным доменом 4 человеческого csf-1r, и их применение | |
| PH12015501763A1 (en) | Humanized anti-factor d antibodies and uses thereof | |
| JP2017176174A5 (OSRAM) | ||
| RU2012129735A (ru) | Антитела к her3 и их применения | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| EA200702327A1 (ru) | Антитела к миостатину | |
| RU2011129204A (ru) | Антитела против ангиопоэтина-2 человека | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| MX2009001110A (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos. | |
| JP2014534239A5 (OSRAM) | ||
| JP2017511130A5 (OSRAM) | ||
| EP2377555A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| JP2014533239A5 (OSRAM) | ||
| MY160892A (en) | Antibodies to ccr2 | |
| EA201200548A1 (ru) | Биспецифические связывающие молекулы для антиангиогенезной терапии | |
| RU2430111C3 (ru) | Молекулы антител с улучшенными свойствами | |
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| JP2014518883A5 (OSRAM) |